Pembrolizumab is a humanized IgG4κ monoclonal antibody that targets the programmed cell death ligands 1 and 2 (PDL-1; PDL-2) pathway, which is frequently taken over by cancer cells to avoid the immune system. Here, CD274 is linked to cancer.